Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors
US12390464B2 · kind B2 · utility
0Cited by
2References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 23, 2020 |
| Grant date | Aug 19, 2025 |
| Priority date | — |
| Expiry date | Aug 18, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating EGFR mutant-related cancers with a combination of an EGFR inhibitor of Formula (I) and the CDK4/6 inhibitor of Formula (II) and use of combinations of these compounds in the manufacture of medicaments for the treatment of EGFR mutant-related cancers are disclosed:
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.